News articles about OraSure Technologies (NASDAQ:OSUR) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. OraSure Technologies earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.1920966144186 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Shares of OraSure Technologies (NASDAQ:OSUR) traded up $0.42 on Friday, hitting $18.00. The stock had a trading volume of 1,872,076 shares, compared to its average volume of 683,603. The company has a market cap of $1,066.20, a P/E ratio of 35.29, a PEG ratio of 3.91 and a beta of 1.43. OraSure Technologies has a 12-month low of $9.92 and a 12-month high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. The firm had revenue of $52.00 million during the quarter, compared to the consensus estimate of $50.20 million. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The company’s revenue for the quarter was up 46.5% on a year-over-year basis. During the same quarter last year, the company posted $0.13 EPS. sell-side analysts forecast that OraSure Technologies will post 0.36 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on OSUR shares. Jefferies Group reiterated a “buy” rating and set a $23.00 price target on shares of OraSure Technologies in a research report on Friday, October 20th. Zacks Investment Research upgraded OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research report on Wednesday, October 25th. ValuEngine downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BidaskClub upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $24.00 price target on shares of OraSure Technologies in a research report on Friday, February 2nd. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $22.25.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/02/10/orasure-technologies-osur-getting-somewhat-positive-press-coverage-accern-reports.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.